Search 

HEC Pharm is the pharmaceutical subsidiaries of HEC Group. There has been a public company listed in Hong Kong in HEC Pharm, and another company will be listed in Shanghai next year.

HEC Pharm focuses on the development and commercialization of pharmaceuticals for the therapeutics of anti-infectious diseases, metabolism disorders and oncology. We are hunting for the opportunities of co-development and in-license of the candidates with the potential therapeutics in previous fields.

Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of On the market innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through Licensing-in and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business, (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.

Innovative biologics for cancer and other patients' unmet needs

We are into Mabs - Biosimilars

focus on biotech,IVD

PE/VC firm

Huahai Investment Co, Ltd is a young, China-based firm backed by the Huahai Pharmaceuticals Group, a listed company in the Shanghai Stock Exchange. Our twin missions are to make investment as well as partnership deals in the healthcare sector.

We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders

Idience Co. Ltd. (“Idience’) is a NRDO (No Research & Development Only) company focusing on oncology treatment. The company was established in 2019 by Ildong Holdings Group, a holding company of leading pharmaceutical and healthcare companies in South Korea.

Our first asset, IDX-1197 is a PARP inhibitor for various solid cancers including breast cancer and ovarian cancer. Its ongoing Phase 1a multi-center study showed a promising result. In October 2019, Idience received approval for its initial Investigational New Drug (IND) application from the Korea Ministry of Food and Drug Safety to start a Phase 1b/2a clinical trial for IDX-1197.

Idience is looking for corporate partners to discover and develop oncology therapeutics. We are open to all license-in and license-out partners.